Related Experiment Videos
Future perspectives in specific immunotherapy of melanoma
1Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
European Journal of Cancer (Oxford, England : 1990)
|December 16, 1998
Summary
Specific immunotherapy using tumour-associated antigens (TAAs) shows promise for melanoma treatment. Further research and development of response markers are crucial for clinical application.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Growing interest in specific immunotherapy for malignancies.
- Focus on melanoma-associated antigens due to immune system's role in melanoma.
- Need for comprehensive review of melanoma antigens and immunotherapy.
Purpose of the Study:
- Review different types of melanoma antigens.
- Summarize their immunogenicity (in vitro and in vivo).
- Analyze clinical data of specific immunotherapy for melanoma patients (Stage I-IV).
Main Methods:
- Literature review of studies on melanoma antigens.
- Analysis of immunogenicity data.
- Compilation and assessment of clinical trial results for immunotherapy.
Main Results:
- Identified various types of melanoma antigens.
- Documented their immunogenicity.
- Clinical study results are variable but suggest potential.
Conclusions:
- Specific immunotherapy for melanoma is an evolving field.
- Variable clinical outcomes necessitate further investigation.
- Development of response correlates is essential for future success.